# US Insulin Pump Market > US Insulin Pump Market Research Report: Size, Share, Trend Analysis By Types (Patch Pumps and Tethered Pumps), By Product (MiniMed, Accu-Chek, Tandem, Omnipod, My life omnipod and Others), By Accessories (Insulin reservoirs or cartridges, Insulin set insertion devices and Battery), By End-user (Hospitals & Clinics, Homecare and Laboratories) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 13.45% - **2024:** $ 1,340 Million - **2025:** $ 1,520.23 Million - **2035:** $ 5,370 Million - **Key Players:** Medtronic(US), Insulet (US), Roche (CH), Tandem Diabetes (US), Ypsomed (CH), A. Menarini Diagnostics (IT), Diabeloop (FR), Beta Bionics (US) **Report ID:** MRFR/MED/11586-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-insulin-pump-market-13111 --- ## Market Summary ## **US Insulin Pump Market Overview** US Insulin Pump Market Size was valued at USD 2.7 Billion in 2022. The Insulin Pump market industry is projected to grow from USD 3.17 Billion in 2023 to USD 11.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 17.50% during the forecast period (2023 - 2032). The rising prevalence of diabetes, the growing preference for insulin pumps among patients, and the growing awareness of insulin pumps for better health are the main market drivers anticipated to propel the Insulin Pump market in the United States.  Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **Insulin Pump Market Trends** - **Growth in the popularity of wearable insulin pumps is driving the market growth.** The market's growth in the popularity of wearable insulin pumps is influencing its growth. Traditional insulin pumps were typically connected to external devices and carried in a separate pouch, but wearable pumps are designed to integrate seamlessly into the user's lifestyle. These devices are compact, discreet, and can be worn directly on the body, offering greater convenience and comfort for individuals with diabetes. The shift towards wearable insulin pumps reflects a growing demand for solutions that prioritize patient comfort and encourage consistent insulin therapy adherence. Moreover, wireless connectivity enables seamless communication with other devices, such as smartphones and continuous glucose monitoring systems, providing users with real-time insights and control over their diabetes management. Furthermore, the US is increasingly adopting hybrid closed-loop systems called artificial pancreas systems. These systems join insulin pumps with continuous glucose monitoring devices, creating a closed-loop feedback system. The CGM continuously measures glucose levels, and the integrated algorithm automatically adjusts insulin delivery in response to these real-time readings. This closed-loop functionality helps maintain blood glucose levels within a target range without constant manual intervention. As a result, individuals with diabetes experience improved stability in glycemic control and a reduced risk of complications. The convenience and enhanced automation offered by hybrid closed-loop systems contribute to better patient compliance and overall satisfaction. Thus driving the Insulin Pump market revenue. ## **Insulin Pump Market Segment Insights** ### **Insulin Pump Type Insights** The US Insulin Pump market segmentation, based on type, includes Patch pumps and Tethered pumps. The patch pumps segment mostly dominated the market. It represents an innovative insulin delivery system that adheres directly to the skin, offering discreet and convenient administration for individuals managing diabetes. These pumps provide a viable alternative to traditional insulin pump options, contributing to the market's diversification of insulin delivery methods. Their user-friendly design and potential benefits make patch pumps an increasingly relevant segment in the diabetes management landscape. ### **Insulin Pump Product Insights** The US Insulin Pump market segmentation, based on product, includes MiniMed, Accu-Chek, Tandem, Omnipod, My Life Omnipod, and Others. The MiniMed category generated the most income. It is a leading insulin pump brand that offers innovative solutions for diabetes management. MiniMed insulin pumps contribute significantly to the market's growth because they are renowned for their user-friendly design and advanced features. With a focus on patient convenience and improved outcomes, MiniMed remains a key player in shaping the landscape of insulin pump products in the United States. ### **Insulin Pump Accessories Insights** The US Insulin Pump market segmentation, based on accessories, includes insulin reservoirs or cartridges, Insulin set insertion devices, and batteries. The insulin reservoirs or cartridges segment generated the most income. It plays a pivotal role in efficiently delivering Insulin to patients using insulin pumps. Understanding the market dynamics and preferences related to insulin reservoirs or cartridges is essential for manufacturers and healthcare providers to meet the specific needs of individuals managing diabetes through insulin pump therapy. ### **Insulin Pump End-user Insights** The US Insulin Pump market segmentation, based on end-users, includes Hospitals and clinics, Homecare and Laboratories. The hospitals & clinics category had the most income. As key stakeholders in diabetes management, hospitals, and clinics serve as crucial settings for the administration, monitoring, and education related to insulin pump therapy. This segment reflects the integral role of healthcare facilities in facilitating access to advanced diabetes care through insulin pump solutions in the US market. **Figure 1: US Insulin Pump Market, by End-user, 2022 & 2032 (USD Billion)** **** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ### **Insulin Pump Country Insights** With a rising prevalence of diabetes, the demand for insulin pumps continues to grow, driven by innovations in technology and a shift towards more convenient and efficient diabetes management. It is characterized by a competitive landscape, with key players introducing innovative features such as continuous glucose monitoring and smartphone integration. Additionally, favorable reimbursement policies and increasing awareness among healthcare professionals and patients contribute to market expansion. The US insulin pump market is poised for further growth, fueled by ongoing research and development, emphasizing user-friendly designs and enhanced connectivity. As the industry continues to address the evolving needs of diabetes management, collaborations between manufacturers and healthcare providers are likely to play a pivotal role in shaping the market's trajectory. **Insulin Pump Key Market Players & Competitive Insights** Leading market players are investing majorly in research and development to spread their product lines, which will help the Insulin Pump market grow even more. The participants are also undertaking various strategic activities to spread their footprint with new market developments, including product launches, contractual agreements, mergers and acquisitions, major investments, and collaboration with other organizations. The Insulin Pump industry must offer cost-effective items to spread and survive in a competitive and rising market climate. The players in the Insulin Pump market are attempting to raise market demand by investing in research and development operations, including Medtronic PLC, Hoffmann-La Roche Ltd., Tandem Diabetic Care, Inc., Insulet Corporation, Ypsomed, Cellenovo, Sooil Development, Valeritas, Inc., and Jingasu Delfu Co., Ltd. **Key Companies in the Insulin Pump market include** **Insulin Pump Industry Developments** **June 2022:** Diabeloop, a leading company in therapeutic AI, and SOOIL Development Company, a leading company in superior diabetes therapy, Proposed an agreement for the development at the American Diabetes Association Scientific Sessions. It is anticipated that clinical trials will be established to spread their cooperation and provide access to their goods to as many plepeople as possible through new innovative products. ## **Insulin Pump Market Segmentation** ### **Insulin Pump Type Outlook** ### **Insulin Pump Product Outlook** ### **Insulin Pump Accessories Outlook** ### **Insulin Pump End-user Outlook** ## Market Drivers ### Rising Investment in Diabetes Care Technologies Investment in diabetes care technologies is on the rise, significantly influencing the insulin pump market. Venture capital funding and government grants are increasingly directed towards the development of innovative diabetes management solutions. In 2025, it is estimated that investments in diabetes technology will exceed $2 billion in the US alone. This influx of capital is expected to accelerate research and development efforts, leading to the introduction of more advanced insulin pumps. As a result, The insulin pump market is expected to experience a diversification of product offerings, catering to a wider range of patient needs and preferences. ### Growing Awareness of Diabetes Management Options There is a growing awareness among patients and healthcare professionals regarding the various diabetes management options available, which is positively impacting the insulin pump market. Educational initiatives and outreach programs have increased knowledge about the benefits of insulin pumps, leading to higher adoption rates. Recent surveys indicate that nearly 40% of healthcare providers recommend insulin pumps as a viable option for diabetes management. This heightened awareness is likely to drive market growth as more patients seek effective solutions to manage their condition. The insulin pump market is well-positioned to benefit from this trend, as it aligns with the broader movement towards proactive health management. ### Enhanced Reimbursement Policies for Diabetes Devices Enhanced reimbursement policies for diabetes devices are emerging as a crucial driver for the insulin pump market. Insurance companies are increasingly recognizing the long-term cost savings associated with insulin pumps, leading to improved coverage options for patients. Recent changes in reimbursement frameworks have made it easier for patients to access insulin pumps, thereby increasing their adoption. As of 2025, it is projected that over 60% of insurance plans will offer comprehensive coverage for insulin pumps, which could significantly boost market growth. This trend indicates a shift towards supporting advanced diabetes management technologies, further solidifying the insulin pump market's position in the healthcare landscape. ### Technological Innovations in Insulin Delivery Systems Technological innovations are playing a pivotal role in shaping the insulin pump market. The introduction of smart insulin pumps, which integrate with mobile applications and continuous glucose monitoring systems, is revolutionizing diabetes management. These devices provide real-time data and analytics, allowing users to make informed decisions about their insulin delivery. The market for insulin pumps is projected to grow at a CAGR of 8% over the next five years, driven by these advancements. Furthermore, the incorporation of artificial intelligence in insulin delivery systems is expected to enhance the accuracy and efficiency of insulin administration, thereby attracting more users to the insulin pump market. ### Increasing Demand for Personalized Diabetes Management The insulin pump market is experiencing a notable surge in demand for personalized diabetes management solutions. Patients are increasingly seeking devices that cater to their specific needs, which has led to a rise in the adoption of insulin pumps. According to recent data, approximately 30% of individuals with diabetes in the US are now using insulin pumps, reflecting a shift towards more tailored treatment options. This trend is driven by the desire for improved glycemic control and the convenience that insulin pumps offer. As healthcare providers emphasize individualized care, the insulin pump market is likely to expand further, with manufacturers focusing on developing advanced features that enhance user experience and outcomes. ## Future Outlook The insulin pump market is projected to grow at a 13.45% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and rising patient awareness. **New opportunities:** - Development of integrated telehealth platforms for [remote patient monitoring](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905) and support. Expansion into emerging markets with affordable insulin pump solutions. Partnerships with healthcare providers for bundled service offerings. By 2035, the insulin pump market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Continuous Glucose Monitoring (Largest) vs. Insulin Delivery (Fastest-Growing) In the US insulin pump market, the application segment is notably diverse, with Continuous Glucose Monitoring (CGM) dominating the landscape. This application holds the largest share, driven by the growing adoption of integrated systems that combine CGM with insulin delivery, enhancing patient outcomes. Insulin Delivery, while currently smaller in market share compared to CGM, is rapidly gaining traction as technological advancements improve its efficiency and user-friendliness, highlighting a significant shift in consumer preferences toward more effective management solutions. Insulin Delivery (Dominant) vs. Data Management (Emerging) Insulin Delivery stands out as the dominant application within the US insulin pump market, as it is integral to the effective treatment of diabetes. This segment thrives on evolving technologies that provide precise and customizable insulin dosages, catering to the individual needs of users. Meanwhile, Data Management is emerging as a critical focus area, with increasing emphasis on tracking and analyzing glucose levels and insulin usage, which enhances treatment personalization. Together, these applications illustrate a comprehensive approach to diabetes management, bridging immediate insulin delivery needs with long-term data insights. ### By End Use: Home Care (Largest) vs. Diabetes Clinics (Fastest-Growing) In the US insulin pump market, the distribution of market share across end-use segments reveals that Home Care stands out as the largest segment, capturing a significant portion of the overall market. This segment benefits from the increasing trend of at-home diabetes management, which is appealing to patients seeking comfort and convenience. Meanwhile, Diabetes Clinics are emerging as the fastest-growing segment, driven by a rising demand for specialized diabetes care and educational support akin to a community setting. Growth trends in this segment indicate a strong shift toward patient-centric care models, with a noticeable increase in insulin pump adoption among various end-user demographics. Home Care remains sustained by technological advancements in pump design and functionality, making it more user-friendly. Meanwhile, Diabetes Clinics see surge due to their ability to provide comprehensive treatment options and personalized patient education, enhancing adherence and management of diabetes effectively. Home Care (Dominant) vs. Diabetes Clinics (Emerging) The Home Care segment in the US insulin pump market is characterized by its focus on providing diabetes patients with the tools they need for effective self-management of insulin delivery at home. This segment benefits from technological advancements, leading to the development of user-friendly insulin pumps that facilitate seamless integration into daily life. In contrast, Diabetes Clinics represent an emerging segment that is gaining traction owing to the growing awareness of diabetes education and the need for personalized treatment solutions. These clinics offer specialized support services and have begun adopting advanced insulin pump technologies, thus attracting new patients and contributing to their rapid expansion in the market. ### By Technology: Smart Insulin Pumps (Largest) vs. Hybrid Closed-Loop Systems (Fastest-Growing) In the US insulin pump market, Smart Insulin Pumps hold the largest share, catering to a growing population of tech-savvy individuals seeking enhanced diabetes management solutions. Traditional Insulin Pumps and Tubeless Insulin Pumps follow, with each segment contributing uniquely to the market landscape. The current market has seen a transition where consumers increasingly prefer devices that offer advanced monitoring and connectivity features, indicating a shift away from more conventional options. Technology: Smart Insulin Pumps (Dominant) vs. Hybrid Closed-Loop Systems (Emerging) Smart Insulin Pumps are designed with advanced technology, incorporating features such as wireless connectivity and data tracking, making them the dominant choice among users in the US insulin pump market. These devices provide real-time glucose monitoring and can be integrated with mobile apps for better management. In contrast, Hybrid Closed-Loop Systems are emerging rapidly, representing innovative technology that combines automated insulin delivery and user inputs. This segment appeals to those looking for a more hands-off approach, leveraging algorithms for optimum insulin dosing, suggesting a shift towards more automated and user-friendly diabetes management solutions. ### By Patient Type: Type 1 Diabetes (Largest) vs. Type 2 Diabetes (Fastest-Growing) The US insulin pump market is primarily driven by the prevalence of Type 1 diabetes, which holds the largest share within the patient type segment. A significant portion of insulin pump users are individuals diagnosed with Type 1 diabetes, as these patients require more intensive insulin management. In comparison, Type 2 diabetes is witnessing a swift increase in adoption of insulin pump therapy, indicating a shift in treatment paradigms. This has positioned it as a rapidly growing segment within the market. Type 1 Diabetes (Dominant) vs. Type 2 Diabetes (Emerging) Type 1 diabetes patients dominate the insulin pump market due to their lifelong dependence on insulin therapy. These individuals typically require frequent monitoring and precise insulin delivery, making insulin pumps an indispensable part of their daily lives. On the other hand, Type 2 diabetes is emerging as a significant segment as more patients, previously managed with oral medications, are transitioning to insulin therapy. The growing awareness of the benefits of insulin pumps—such as improved glycemic control and convenience—has spurred this trend, indicating a shift in treatment strategies and expanding market potential for insulin pumps among Type 2 diabetes patients. ### By Distribution Channel: Online Retail (Largest) vs. Pharmacies (Fastest-Growing) In the US insulin pump market, the distribution channels exhibit a diverse landscape with online retail establishing itself as the dominant player, commanding significant market share. In contrast, pharmacies are rapidly emerging as a vital channel, increasing their accessibility to consumers. Medical supply stores and direct sales also contribute to the overall distribution framework, but they lag behind in market share compared to online platforms and pharmacies. Online Retail (Dominant) vs. Pharmacies (Emerging) Online retail stands out as the dominant distribution channel due to its convenience and extensive reach, allowing patients to easily access a range of insulin pump options. This growth is fueled by the increasing consumer preference for online shopping and the ability to compare products and prices seamlessly. On the other hand, pharmacies represent an emerging channel, rapidly expanding their role in distributing insulin pumps. They are becoming popular for their personalized service and accessibility, appealing to patients who prefer in-person consultations and immediate access to their devices. ## Regional Market Share Analysis ### North America : Market Leader in Innovation The North American insulin pump market is driven by technological advancements, increasing diabetes prevalence, and supportive regulatory frameworks. The U.S. holds the largest market share at approximately 70%, followed by Canada at around 15%. The demand for insulin pumps is bolstered by rising awareness of diabetes management and the growing adoption of continuous glucose monitoring systems. Regulatory support from the FDA further enhances market growth, ensuring safety and efficacy in new product launches. The competitive landscape is characterized by major players such as Medtronic, Insulet Corporation, and Tandem Diabetes Care, which dominate the market with innovative products. These companies are continuously investing in research and development to enhance product features and patient experience. The presence of established healthcare infrastructure and reimbursement policies also supports the growth of insulin pump adoption in the region. ### Europe : Emerging Market with Growth Potential The European insulin pump market is witnessing significant growth, driven by increasing diabetes cases and favorable regulatory environments. Germany and the UK are the largest markets, holding approximately 25% and 20% market shares, respectively. The European Medicines Agency (EMA) has been instrumental in streamlining the approval process for innovative diabetes management devices, which encourages market entry and expansion. The rising focus on personalized medicine and patient-centric solutions further propels demand for insulin pumps across the region. Leading countries in Europe include Germany, the UK, and France, with a competitive landscape featuring key players like Roche Diabetes Care and Abbott Laboratories. The market is characterized by a mix of established companies and emerging startups, fostering innovation. Collaborations between healthcare providers and technology firms are enhancing product offerings, while increasing awareness of diabetes management solutions drives adoption rates across the continent. ### Asia-Pacific : Rapidly Growing Diabetes Market The Asia-Pacific insulin pump market is rapidly expanding, driven by rising diabetes prevalence and increasing healthcare expenditure. Countries like China and India are leading the market, with China holding approximately 30% of the regional share, followed by India at around 20%. The growing awareness of diabetes management and the introduction of advanced insulin delivery systems are key factors contributing to this growth. Government initiatives aimed at improving healthcare access also play a crucial role in market expansion. The competitive landscape in Asia-Pacific is evolving, with both The US Insulin Pump Market share. Companies such as Becton Dickinson and Ypsomed are making significant inroads, while local manufacturers are emerging to cater to the unique needs of the region. The increasing focus on technological advancements and affordability is driving innovation, making insulin pumps more accessible to a broader population. ### Middle East and Africa : Untapped Market Potential The Middle East and Africa insulin pump market is in its nascent stages but shows promising growth potential. The region faces a high prevalence of diabetes, with countries like South Africa and the UAE leading the market. South Africa holds approximately 15% of the regional market share, while the UAE follows closely at around 10%. The increasing awareness of diabetes management and the need for advanced treatment options are driving demand for insulin pumps. Government initiatives aimed at improving healthcare infrastructure are also contributing to market growth. The competitive landscape is characterized by a mix of international and local players, with companies like AstraZeneca and Ypsomed making significant contributions. The market is gradually evolving, with a focus on education and awareness programs to promote insulin pump adoption. As healthcare systems improve and access to technology increases, the insulin pump market in the region is expected to expand significantly in the coming years. ## Competitive Benchmarking The insulin pump market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for diabetes management solutions. Key players such as Medtronic (US), Insulet (US), and Tandem Diabetes (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Medtronic (US) focuses on innovation through continuous product development, particularly in integrating advanced algorithms for insulin delivery. Insulet (US), known for its Omnipod system, emphasizes user-friendly designs and expanding its market reach through strategic partnerships. Tandem Diabetes (US) leverages digital health technologies, enhancing user experience with its t:slim X2 insulin pump, which integrates seamlessly with continuous glucose monitoring systems. Collectively, these strategies foster a competitive environment that prioritizes innovation and user-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing to mitigate supply chain disruptions and optimize operational efficiency. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that significantly influence pricing and product offerings. This competitive structure allows for a diverse range of products, catering to varying consumer needs while also fostering innovation through competition. In October Medtronic (US) announced the launch of its latest insulin pump model, which features enhanced connectivity with mobile applications, allowing users to monitor their glucose levels in real-time. This strategic move is likely to strengthen Medtronic's position in the market by appealing to tech-savvy consumers who prioritize integrated health solutions. The emphasis on connectivity aligns with broader trends in digital health, suggesting a shift towards more interactive and user-friendly diabetes management tools. In September Insulet (US) expanded its partnership with a leading telehealth provider to offer remote monitoring services for its Omnipod users. This collaboration is significant as it not only enhances the value proposition of Insulet's products but also addresses the growing demand for telehealth solutions in chronic disease management. By integrating telehealth capabilities, Insulet positions itself as a forward-thinking player in the market, likely attracting a broader customer base. In August Tandem Diabetes (US) secured a strategic investment to further develop its artificial intelligence-driven insulin delivery systems. This investment is pivotal, as it underscores the increasing importance of AI in personalizing diabetes management. By focusing on AI integration, Tandem Diabetes is poised to differentiate itself in a competitive landscape that is rapidly evolving towards more sophisticated and automated solutions. As of November current trends in the insulin pump market indicate a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly vital, as companies seek to enhance their product offerings and expand their market reach. The competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these aspects will be better positioned to thrive in the future. ## Recent News & Developments **June 2022:** Diabeloop, a leading company in therapeutic AI, and SOOIL Development Company, a leading company in superior diabetes therapy, Proposed an agreement for the development at the American Diabetes Association Scientific Sessions. It is anticipated that clinical trials will be established to spread their cooperation and provide access to their goods to as many plepeople as possible through new innovative products. ## Report Scope | MARKET SIZE 2024 | 1340.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1520.23(USD Million) | | MARKET SIZE 2035 | 5370.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.45% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Medtronic (US), Insulet (US), Roche (CH), Tandem Diabetes (US), Ypsomed (CH), A. Menarini Diagnostics (IT), Diabeloop (FR), Beta Bionics (US) | | Segments Covered | Type, Technology, End User, Component | | Key Market Opportunities | Integration of advanced digital health technologies enhances patient engagement in the insulin pump market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the insulin pump market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US insulin pump market in 2024?** A: The market valuation of the US insulin pump market was $1340.0 Million in 2024. **Q: What is the projected market valuation for the US insulin pump market in 2035?** A: The projected market valuation for the US insulin pump market is $5370.0 Million in 2035. **Q: What is the expected CAGR for the US insulin pump market during the forecast period 2025 - 2035?** A: The expected CAGR for the US insulin pump market during the forecast period 2025 - 2035 is 13.45%. **Q: Which companies are considered key players in the US insulin pump market?** A: Key players in the US insulin pump market include Medtronic, Insulet, Roche, Tandem Diabetes, Ypsomed, A. Menarini Diagnostics, Diabeloop, and Beta Bionics. **Q: What are the market segments for insulin pumps based on type?** A: The market segments for insulin pumps based on type include Tethered Insulin Pumps, Patch Insulin Pumps, and Implantable Insulin Pumps. **Q: What was the market value of Tethered Insulin Pumps in 2024?** A: The market value of Tethered Insulin Pumps was $600.0 Million in 2024. **Q: What is the projected market value for Smart Insulin Pumps in 2035?** A: The projected market value for Smart Insulin Pumps is $2400.0 Million in 2035. **Q: How much was the market value for Continuous Glucose Monitoring in 2024?** A: The market value for Continuous Glucose Monitoring was $400.0 Million in 2024. **Q: What is the expected market value for Infusion Sets in 2035?** A: The expected market value for Infusion Sets is $2400.0 Million in 2035. **Q: What segment had the highest market value in 2024 among end users?** A: Among end users, Adults had the highest market value at $670.0 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-insulin-pump-market-13111*